Why Anbio Biotechnology’s (NNNN) Stock Is Down 6.67%
As of Friday, July 17, Anbio Biotechnology’s NNNN share price has dipped by 6.67%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Commentary & Analysis
Why Anbio Biotechnology’s (NNNN) Stock Is Up 11.29%
As of Thursday, July 16, Anbio Biotechnology’s NNNN share price has surged by 11.29%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Anbio Biotechnology’s (NNNN) Stock Is Up 10.75%
As of Thursday, July 16, Anbio Biotechnology’s NNNN share price has surged by 10.75%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Anbio Biotechnology’s (NNNN) Stock Is Down 5.92%
As of Tuesday, July 14, Anbio Biotechnology’s NNNN share price has dipped by 5.92%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Anbio Biotechnology’s (NNNN) Stock Is Up 5.40%
As of Tuesday, July 07, Anbio Biotechnology’s NNNN share price has surged by 5.40%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | NNNN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $444.6 | $252.6 | 36% |
|
| Shares Out (Mil) | 43.9 | 52.3 | 45% |
|
| Institutional Ownership | na | 92.1% | na |
|
| Float (Mil) | 39.7 | 40.2 | 42% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 39 | 455 | 26% |
|
| Price Change (52-week) |
(75.9%) | 52.9% | 8% |
|
| Growth | NNNN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NNNN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $9 | $38 | 8% |
|
| Net Income (TTM) (Mil) | $6 | ($43) | 44% |
|
| EPS (TTM) | $0.147 | ($1.600) | 45% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($31) | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $546 | $180 | 35% |
|
| Valuation | NNNN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 14.68 | 2.56 | 93% |
|
| P/E | 68.9 | 19.0 | 89% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | NNNN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 87.2% | 63.8% | 92% |
|
| Net Margin | 74.1% | (67.3%) | 99% |
|
| ROA | 26.0% | (49.8%) | 98% |
|
| ROE | 26.4% | (55.5%) | 85% |
|
| Liabilities to Assets | 0.3% | 30.3% | 0% |
|
| F-Score | 4 | 3 | 34% |
|
Anbio Biotechnology did not pass any screens on 7/31/2026.
